Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live

ABSTRACT Zoster Vaccine Live (ZVL) is marketed in the US since 2008, and a non-live adjuvanted Recombinant Zoster Vaccine (RZV) was approved in 2017. Literature suggests that waning of ZVL efficacy may necessitate additional vaccination. The Advisory Committee on Immunization Practices recommended vaccination with RZV in immunocompetent adults aged 50+ years old, including those previously vaccinated with ZVL. The objective of this study was to determine the cost-effectiveness of vaccinating US adults aged 60+ years old, previously vaccinated with ZVL. The ZOster ecoNomic Analysis (ZONA) model, a deterministic Markov model, was adapted to follow a hypothetical 1 million(M)-person cohort of US adults previously vaccinated with ZVL. Model inputs included demographics, epidemiology, vaccine characteristics, utilities and costs. Costs and quality-adjusted life-years (QALYs) were presented over the lifetimes of the cohort from the year of additional vaccination, discounted 3% annually. The model estimated that, vaccination with RZV 5 years after previous vaccination with ZVL, would reduce disease burden compared with no additional vaccination, resulting in a gain of 1,633 QALYs at a total societal cost of $96M (incremental cost-effectiveness ratio: $58,793/QALY saved). Compared with revaccinating with ZVL, vaccination with RZV would result in a gain of 1,187 QALYs and societal cost savings of almost $84M. Sensitivity, scenario, and threshold analyses demonstrated robustness of these findings. Vaccination with RZV is predicted to be cost-effective relative to no additional vaccination, assuming a threshold of $100,000/QALY, and cost-saving relative to ZVL revaccination of US adults aged 60+ years old who have been previously vaccinated with ZVL.

[1]  B. Yawn,et al.  Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States. , 2018, Vaccine.

[2]  T. Mrkvan,et al.  The Comparative Efficacy, Safety, And Reactogenicity, of Herpes Zoster Vaccines: A Network Meta-Analysis , 2018 .

[3]  M. Rothberg,et al.  Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults , 2018, JAMA internal medicine.

[4]  E. Belongia,et al.  Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines , 2018, MMWR. Morbidity and mortality weekly report.

[5]  M. Rothberg,et al.  Cost Effectiveness of a Shingles Vaccine Booster for Currently Vaccinated Adults in the U.S. , 2017, American journal of preventive medicine.

[6]  L. Prosser Economic Evaluation of Vaccination for Prevention of Herpes Zoster and Related Complications , 2017 .

[7]  L. Cámpora,et al.  Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine , 2017, The Journal of infectious diseases.

[8]  T. Mrkvan,et al.  Assessment of the potential public health impact of Herpes Zoster vaccination in Germany , 2017, Human vaccines & immunotherapeutics.

[9]  D. Curran,et al.  The temporal impact of aging on the burden of herpes zoster , 2017, BMC Geriatrics.

[10]  C. Bridges,et al.  Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017. , 2017, Annals of internal medicine.

[11]  B. Fireman,et al.  EFFECTIVENESS OF LIVE ZOSTER VACCINE IN PREVENTING POSTHERPETIC NEURALGIA (PHN) , 2016 .

[12]  Lidia Oostvogels,et al.  Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. , 2016, The New England journal of medicine.

[13]  Craig M. Hales,et al.  Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years. , 2016, The Journal of infectious diseases.

[14]  J. McLaughlin,et al.  Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013 , 2015, The Journal of Primary Prevention.

[15]  Shinn-Jang Hwang,et al.  Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. , 2015, The New England journal of medicine.

[16]  K. Schmader,et al.  Long-term persistence of zoster vaccine efficacy. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  R. Kessler,et al.  Self-Reported Population Health: An International Perspective based on EQ-5D , 2014, Springer Netherlands.

[18]  H. Doerr Progress in VZV vaccination? Some concerns , 2013, Medical Microbiology and Immunology.

[19]  L. Sy,et al.  Work and productivity loss related to herpes zoster , 2011, Journal of medical economics.

[20]  B. Yawn,et al.  Health care utilization and cost burden of herpes zoster in a community population. , 2009, Mayo Clinic proceedings.

[21]  M. Oxman Herpes Zoster Pathogenesis and Cell-Mediated Immunity and Immunosenescence , 2009, The Journal of the American Osteopathic Association.

[22]  Atlanta,et al.  Morbidity and Mortality Weekly Report Prevention of Herpes Zoster Recommendations of the Advisory Committee on Immunization Practices (acip) Inside: Continuing Education Examination Centers for Disease Control and Prevention Centers for Disease Control and Prevention Centers for Disease Control and , 2022 .

[23]  M. Brisson,et al.  Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. , 2007, Vaccine.

[24]  D. Kimberlin,et al.  Varicella-zoster vaccine for the prevention of herpes zoster. , 2007, The New England journal of medicine.

[25]  NATIONAL CENTRE FOR HEALTH STATISTICS , 1974 .